Successful Transapical Transcatheter Valve Implantation Within a Dysfunctional Mitral Bioprosthesis  by de Weger, Arend et al.
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uccessful Transapical
ranscatheter Valve Implantation
ithin a Dysfunctional
itral Bioprosthesis
he valve-in-valve concept is an emerging therapeutic option
or patients with degenerative failure of previously implanted
enografts. Reoperation of degenerated bioprostheses has a
igh mortality risk that increases with the age and associated
omorbidities of the patients. The transcatheter valve-in-valve
mplantation does not need resternotomy or cardiopulmonary
ypass, potentially reducing the morbidity and mortality risk.
owever, unlike the transcatheter implants in native valves, in
he valve-in-valve procedures, the leaflets and calcified annulus
re replaced with the rigid annulus of the xenograft. This
equires accurate sizing of the transcatheter valve, currently
vailable in 2 sizes. Therefore, 3-dimensional imaging tech-
iques, particularly multi-detector row computed tomography
MDCT), may provide a more exact sizing of the host
enograft ring. We report a mitral valve-in-valve procedure in
79-year-old female patient with previous aortic and mitral
alve replacement (a 21-mm and a 27-mm Medtronic Mosaic
ioprosthetic valve [Medtronic Inc., Minneapolis, Minne-
ota], respectively). Transesophageal echocardiography re-
ealed severe mitral regurgitation secondary to a degenerative
ail bioprosthesis (Fig. 1A). The patient’s logistic Euro-
CORE was 32% for repeat mitral valve operation. Therefore,
e considered the possibility of performing a transcatheter
alve implantation within the mitral bioprosthesis. During the
election of the appropriate Edwards-Sapien valve size (Ed-
ards Lifesciences Inc., Irvine, California), the internal diam-
ter and length of the pre-existing mitral bioprosthesis using
ultiplanar reconstructions by 320-row MDCT were taken
nto consideration (Fig. 1B). Because the 27-mm Medtronic
osaic bioprosthetic valve (Medtronic Inc.) had an internal
iameter of 24 mm, a 26-mm Edwards-Sapien valve prosthe-
is (Edwards Lifesciences Inc.) was selected. During the
rocedure, due to the absence of a radiopaque annular ring,
he mitral bioprosthesis was only visible on fluoroscopy as 3
mall radiopaque rings on the top of the struts (Fig. 1C).
ecause we could not rely on fluoroscopy alone for precise
alve positioning during implantation of the Edwards-Sapien
D
ralve prosthesis (Edwards Lifesciences Inc.), transesophageal
chocardiography (iE33; Philips Medical Systems, Bothell,
ashington) was performed simultaneously to guide valve
mplantation. To ensure maximal control during delivery and
eployment of the transcatheter valve, the implantation pro-
edure was performed via the transapical approach as previ-
usly described. The 26-mm Edwards-Sapien valve (Edwards
ifesciences Inc.) was successfully deployed in stages within
he prosthesis (Figs. 1D and 1E). Transesophageal echocar-
iography demonstrated minimal paravalvular leakage with a
aximum gradient of 4 mm Hg (Fig. 1F). The patient was
xtubated in the operating room and transferred to the ward
fter 1 day of monitoring in the intensive care unit. Post-
perative recovery was uneventful, and the patient was dis-
harged home on the 11th day. At 1-month follow-up, a
epeat transthoracic echocardiogram showed normal function-
ng transcatheter valve, without leakage and a mean gradient of
mm Hg. With 320-row MDCT, a circular deployment of
he 26-mm Edwards-Sapien valve (Edwards Lifesciences Inc.)
ithin the bioprosthetic mitral valve was demonstrated (Fig.
G). This case illustrates the feasibility of using a transcatheter
alve-in-valve procedure in a dysfunctional mitral bioprosthe-
is and the role of multimodality imaging to accurately select
he prosthesis and to guide the procedure.
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Letter to the Editor 223Figure 1. Transcatheter Mitral Valve-in-Valve Procedure: Multimodality Imaging Evaluation
(A) Transesophageal echocardiography showing severe mitral regurgitation secondary to a degenerative mitral bioprosthesis with ﬂail, noncoapting bioprosthetic
leaﬂets (arrow). (B) Pre-operative computed tomography of the mitral Medtronic Mosaic bioprosthetic valve (Medtronic Inc.) with an internal diameter of 24 mm
and surrounding severe mitral annular calciﬁcation. (C) Fluoroscopic image of the radiolucent mitral Medtronic Mosaic bioprosthetic valve (Medtronic Inc.) with 3
radiopaque rings on top of the valve struts (arrows). (D) Fluoroscopic image of the transcatheter Edwards-Sapien valve (Edwards Lifesciences Inc.) successfully
deployed within the mitral Medtronic Mosaic bioprosthetic valve (Medtronic Inc.). (E) Short-axis ﬂuoroscopic image of the transcatheter Edwards-Sapien valve
(Edwards Lifesciences Inc.) deployed within the mitral Medtronic Mosaic bioprosthetic valve (Medtronic Inc.) with the 3 radiopaque rings on top of the valve struts
(arrows). (F) Post-operative transesophageal echocardiogram showing successful deployment of Edwards-Sapien valve (Edwards Lifesciences Inc.) with no residual
regurgitation. (G) At 1-month follow-up after the procedure, 320-slice computed tomography showed a circular deployment of the 26-mm Edwards-Sapien valve
(Edwards Lifesciences Inc.) within the bioprosthetic mitral valve (right). The 3-dimensional reconstruction of the transcatheter valve surrounded at the lower part
by 3 radiopaque rings of the mitral bioprosthesis (arrows) is shown (left). Ao  aorta; LCx  left circumﬂex coronary artery; LMA  left main coronary artery;
RA  right atrium; RCA  right coronary artery.
